Sansawi, Almoidz Y.

HRN: 22-95-57  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/25/2023
CEFOTAXIME 500MG (VIAL)
04/25/2023
05/01/2023
IVTT
285mg
Q6h
PCAP C, Bfc, T/C Sepsis
Waiting Final Action 

Indication:  Empiric    Type of Infection:  PneumoniaUnspecified Sepsis    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: